期刊
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
卷 31, 期 1, 页码 45-49出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/00126334-200209010-00006
关键词
mycophenolate; nucleoside; resistance; salvage
Mycophenolic acid (MPA) enhances the in vitro activity of abacavir (ABC) and other nucleoside analog reverse transcriptase inhibitors (NRTIs) against sensitive and NRTI-resistant HIV-1. This may occur via depletion of intracellular deoxyguanosine triphosphate (dGTP). Mycophenolate mofetil (MMF) 500 mg twice daily was added as a single agent to the antiretroviral regimens of five patients failing maximal available therapy. Therapy included ABC, and in most cases didanosine (DDI) and tenofovir (TDF). At entry, mean plasma HIV-1 RNA (VL) was 5.02 log(10) copies/mL (median 4.78, range 4.71-5.63) and mean CD4 count was 106/muL (median 117, range 11-174). MMF was well tolerated. CD4 cell counts did not change significantly from baseline for up to 60 weeks of follow-up. Three of five subjects had VL declines of >0.5 log(10) copies/mL immediately after adding MMF; a fourth subject had a sustained decline of >0.5 log(10) copies/mL after week 8. Declines of >0.5 log(10) copies/mL were lost in two patients at 6 and 8 weeks, and persisted in two patients at 36 and 60 weeks of follow-up, respectively. An increase in the ratio of carbovir triphosphate (CBV-TP), the active antiviral metabolite of ABC, to dGTP was documented in 3 of 4 subjects in temporal association with decreased VL. Trough plasma MPA levels ranged from 0.26-1.67 mug/mL; peak levels 90 minutes after dosing from 1.20-7.77 mug/mL. AUC of MPA appeared little changed when measured over 28 weeks of therapy. Declines in VL were observed in association with measurable changes in the CBV-TP/dGTP ratio in some patients, whereas MPA AUC was below the 30-60 mug*hr/mL range targeted in organ transplantation. The possibility that MMF may enhance the effect of selected NRTls and be tolerated in late stage HIV disease deserves careful randomized study.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据